NEW YORK, June 19 - Three weeks after announcing its proposed acquisition of Gemini Genomics, Sequenom provided additional details Tuesday about the combined company's business strategy and financial projections.

In May, San Diego-based Sequenom said that it had agreed to acquire clinical genomics company Gemini Genomics, of Cambridge, UK, for $238 million in stock in an effort to boost the company's drug development and clinical capabilities. 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.